Background: Endovascular coil embolization of cerebral aneurysms is an effective treatment for the prevention of aneurysm rebleeding after subarachnoid hemorrhage. It is also often used in unruptured aneurysms, but it is associated with aneurysm remnants and recurrences in up to 20%-33% of patients. We hypothesized that better aneurysm occlusion rates can be achieved with coils of larger caliber. Methods: The Does Embolization with Larger coils lead to better Treatment of Aneurysms (DELTA) trial is an investigatorinitiated, multicenter, prospective, randomized, controlled clinical trial. To test the hypothesis that 15-caliber coiling systems are superior to 10-caliber coils, 564 patients with aneurysms measuring 4-12 mm will be randomized 1:1 to embolization with either 10-caliber coils exclusively (control group) or the highest safely achievable proportion of 15-caliber coils (intervention group). The primary efficacy endpoint of the trial is the occurrence of a major recurrence or a residual aneurysm at one year. A pilot phase of 165 patients will be conducted to verify feasibility of the coiling strategy, compliance to treatment allocation, safety of a 15-caliber platinum coil embolization strategy, recruitment rates, and the capacity to improve packing density. Discussion: The DELTA trial will test the hypothesis that the use of coils of larger caliber can improve angiographic results of endovascular coiling.
Introduction
Endovascular treatment with platinum coils is effective in preventing rebleeding of intracranial aneurysms in the acute phase after subarachnoid hemorrhage (SAH) 1 and has been a widely accepted practice for the preventive treatment of unruptured aneurysms as well. 2 However, endovascular coil embolization is associated with incomplete occlusion at initial treatment (remnant) or at follow-up (recurrence). 3 Rebleeding from a treated aneurysm has been rare so far (incidence of 1.56 per 1000 patient-years 4 ), but up to 10% of aneurysm remnants or recurrences require retreatment after initial coiling. 5, 6 A number of strategies designed to improve the efficacy of endovascular coiling have been proposed, including second-generation coils with surface modifications such as hydrogel or polylactic coating, but convincing evidence of improved results of coiling remains elusive. 7, 8 First-generation platinum coils come in various sizes, shapes and calibers. Some observational studies have shown that aneurysm remnants and recurrences are less frequent when the aneurysm sac is filled with a larger volume of embolic material. 9, 10 Compared to small-caliber coils, large-caliber coil systems are thought to be capable of increasing the proportion of the aneurysm that can be filled with metal. 11 While larger-caliber coils are typically reserved for the treatment of large aneurysms, and smaller-caliber coils for small aneurysms, softer, larger-caliber coils have now been manufactured to increase platinum filling of relatively small aneurysms. It remains unknown whether use of a large-caliber system can lead to improved packing density and more complete initial treatments, and whether they can potentially decrease one-year recurrence rates. The Does Embolization with Larger coils lead to better Treatment of Aneurysms (DELTA) trial was designed to address these questions.
Methods
The DELTA trial design at a glance DELTA is an investigator-initiated, multicenter, prospective, randomized, controlled clinical trial comparing embolization with 15-caliber coils to embolization with standard 10-caliber coils in patients harboring small to medium size aneurysms ( Figure 1 ). All patients with aneurysm ! 4 and 12 mm or with a recurrence are eligible. Adjudication of angiographic results will be conducted by a committee blinded to treatment allocation in an independent core laboratory. The study will be conducted in 10-25 centers. The study aims to enroll 564 patients equally divided between the two groups (15-caliber platinum coils vs. standard 10-caliber platinum coils), to obtain statistical significance in the primary endpoint (the occurrence of a recurrence at follow-up). The forecast duration of the study will be six years, the first four years for patient recruitment and accrual plus 12 months for follow-up. The pivotal trial will be preceded by a pilot phase of approximately 165 patients, over approximately three years, designed to confirm the safety and feasibility of the coiling strategy, to assess the enrollment rates, and to compare packing densities between the two groups.
Hypotheses
The use of 15-caliber platinum coils will lead to a decrease in the number of patients that reach the primary endpoint from 33% to 20% at 12 AE 2 months. The pilot phase has been powered to test the hypothesis that the use of 15-caliber platinum coils will lead to an increased packing density as compared to 10-caliber coils from an expected mean of 25% to 28% (95% power; alpha 0.05).
Selection criteria
Inclusion criteria are: at least one ruptured or unruptured aneurysm with a dimension ! 4 mm and 12 mm (longest axis), World Federation of Neurosurgical Societies (WFNS) grade < IV for patients with ruptured aneurysm, the anatomy of the lesion is such that endovascular treatment is possible with both types of coils, patient is 18 or older and life expectancy is more than two years. Exclusion criteria are: patients with planned treatment of an associated cerebral arteriovenous malformation, parent vessel occlusion being the primary intent of the procedure, and any absolute contraindication to endovascular treatment, angiography, or anesthesia such as severe allergies to contrast or medications.
Randomization and data storage
DELTA ensures concealment of treatment allocation prior to enrollment by using a 1:1 web-based randomization algorithm, minimizing according to the following criteria: whether the aneurysm is ruptured or not and whether the aneurysm was previously treated or not (major recurrence).
Number of patients
A decrease in the recurrence rate from 33% to 20% would be clinically significant. Based on Fisher's Exact test, 564 patients will be needed to detect a decrease in the recurrence rate from 33% to 20% with an alpha error of 5% and a beta error of 10%, allowing 10% of losses at determination of the primary endpoint.
Pilot phase
A pilot phase of approximately 165 patients is planned to verify the feasibility of the coiling strategy, compliance to treatment group allocation, the safety of a 15-caliber platinum coil embolization strategy, recruitment rates, and the capacity to improve packing density to a mean of 28% with a power of 95% and a two-sided alpha error of 0.05 (assuming the packing density of the control group will be approximately 25%). The data will be reviewed and analyzed by the Data and Safety Monitoring Committee (DSMC) and recommendations will be forwarded to the Steering Committee (SC) regarding continuation into the pivotal second phase of the study.
Interventions
The goal of the study is to assess whether the use of a larger-caliber coil system can reduce the number of patients reaching the primary endpoint compared to the use of smaller-caliber coil system. Thus, the interventions will consist of embolization with either 10-caliber coils or the use of the highest safely achievable proportion of 15-caliber coils. Patients allocated to 15-caliber coiling will preferably receive as many 15caliber coils as safely achievable. The use of Deltamaxx coils (Codman Neuro, Raynham, MA, USA), previously shown to ease the introduction of larger, softer, longer coils into aneurysm models, 11 is encouraged, but any coil from any company can be used, provided it is caliber 0.014 or more. The procedure can be completed with 10-caliber or smaller finishing coils, in order to optimize complete occlusion. Patients allocated to 10-caliber coiling will preferably receive 10-caliber coils in order to optimize complete occlusion, but any coil of any company can be used, provided it is caliber 0.0135 or less. Both groups will receive platinum coils only (the use of coated coils is prohibited). The trial does not require the use of a minimal number or length of coils, nor a threshold ''acceptable'' packing density.
At any time during the procedure the interventionist is unrestricted in the use of any device, technique or drug judged important to the safety and success of the endovascular procedure. If a patient is randomized to 15-caliber coils but, for clinical reasons not initially recognized at the time of recruitment, the operator prefers not to deploy large-caliber coils, he or she would proceed using appropriate coils in the best interests of the patient. The converse is also true. In any such case, the operator records reasons for the change on the case report form (CRF). The use of balloon remodeling or stent-assisted coiling techniques is permitted and this information will also be collected on the CRF. The aim of treatment is the complete angiographic exclusion of the aneurysm, or as complete an exclusion from circulation as is feasible while minimizing risks of the procedure as per practice standards. The interventionist and therefore the clinical and interventional research team cannot be blinded to the nature of the coils used. Parent vessel occlusion concomitant to endosaccular coiling can be performed as long as it was not the primary intent at procedural outset.
Choice of outcome measures
The primary efficacy endpoint of DELTA is the occurrence of a major recurrence or a residual aneurysm at the time of follow-up angiography (12 AE 2 months). An independent committee will adjudicate, for each patient, whether he or she has reached the endpoint. In the absence of follow-up imaging, the committee will adjudicate other potential cases of treatment failures (expected to be rare) such as: failure of the initial procedure, hemorrhage during the follow-up period, retreatment of the same lesion by endovascular or surgical means during the follow-up period, occurrence or progression of a mass effect in relation to the treated aneurysm, and morbidity and mortality that precludes follow-up. The pilot phase of the study is powered to detect a difference of 3% in the mean packing density between the two groups (primary endpoint for the pilot phase).
Secondary outcomes include other indices of immediate treatment success as well as standard safety outcomes: procedure-related serious adverse events (SAEs), initial technical success of the coiling strategy, use of adjunct devices, number and total length of coils implanted for each type, packing density (core lab measured), time of fluoroscopic exposure, immediate angiographic results according to the Montreal scale, modified Rankin Scale (mRS) score at one year follow-up, major recurrence on follow-up angiography, and morbidity and mortality that precludes angiographic follow-up.
Angiographers at each participating center will ensure that best projections showing residual necks at the time of treatment are repeated during follow-up evaluations. For the purpose of this study, only major recurrences or residual aneurysms that are of a size that would necessitate retreatment, as judged by the core lab, will be counted. The inter-rater agreement regarding this dichotomized angiographic endpoint has previously been shown to be acceptable. 12, 13 Angiographic results will be scored according to a previously published classification system 14 as complete obliteration, residual neck or residual aneurysm, and groups will be compared for results initially at the end of treatment and at follow-up at 12 AE 2 months. Recurrences will be recorded (present or absent) on CRFs as they are discovered, either at the routine follow-up assessments or as clinical symptoms appear any time during the 12 months that follow the intervention. The independent core lab will adjudicate the angiographic results.
Initial technical success
For the patients allocated to 15-caliber coils, the interventionists will choose whether to use 15-caliber coils only and/or other coils during the embolization procedure, in order to guarantee the same safety and immediate efficacy as the standard procedure. A failure to perform the intended experimental treatment will be considered to have occurred if < 30% of the total coil length is 15-caliber coils. The initial technical success or failure of the procedure will be determined after treatment by the adjudication committee by reviewing the independent core lab result using the procedural angiogram and the coils used as recorded in the CRF.
Safety outcomes
The death rate will be recorded for the intent-to-treat analyses. Mortality rates will be obtained by dividing the number of deaths by the number of patients in each group. Mortality will be categorized as being (a) related to the illness, (b) related to coil embolization or (c) unrelated. Adverse events are recorded immediately after the procedure and during the 12-month followup period. SAEs, those that are life threatening, leading to hospitalizations or prolonged hospitalizations, as well as unexpected events will all be reported within 48 hours to the data coordination center, which will transmit the information to the DSMC. The number and severity of all reported adverse events will be recorded for each patient and for each treatment group. The number and the severity of morbid events will be recorded for each patient. The mRS score will be measured at follow-up appointments. This scale classifies the patients according to their neurological outcome. 15 
Clinical follow-up and imaging protocol
For the analysis of the safety data, clinical examinations will be recorded at the end of the procedure, at discharge, and at the time of follow-up imaging. Follow-up computed tomography (CT) scan or magnetic resonance imaging (MRI) will be performed at 24 hours or before discharge to detect silent periprocedural events, as normally performed in each institution. When patients are unable or unwilling to come to the hospital for follow-up visits, information may be collected via telephone. The mRS score may be obtained through telephone interviews (using a standardized questionnaire) by the study coordinator. Adverse events are recorded immediately after the procedure and during the 12-month follow-up period. First, the number and nature of adverse events for each patient is recorded. Then the relation to the aneurysm itself, to the endovascular coil embolization (not possibly or probably related) will be recorded. Clinical assessments will include the mRS score at 6-12 months. Follow-up imaging studies will be performed at 12 AE 2 months by either catheter angiography or noninvasive vascular imaging according to the preference of the participating center.
Planned analyses
Descriptive statistics will be performed on demographic variables and perioperative data to compare the two groups at baseline. Means, standard deviations and range will be presented for quantitative variables and frequency tables for categorical variables. Those statistics will be broken down by treatment arm. Comparability of the groups will be assessed through independent analyses of variance (ANOVAs) (quantitative data) or Mantel-Haenszel and chi-square tests (categorical data). For the pilot phase, the number of patients with satisfactory immediate angiographic results (complete occlusion or residual neck), as well as the mean packing density, will be compared between the two groups. The primary outcome of the pivotal phase, intent-to-treat recurrence rates, will be compared between groups through a z-test for independent proportions at 12 months. Secondary outcomes and safety data will be compared between groups through independent t-tests (quantitative variables) or chisquare statistics (categorical data). All tests will be interpreted with adjustment for the interim analysis to have the 0.05 level of confidence at 12 months only. Finally, a logistic regression will be used to find variables capable of predicting recurrences. The method planned is a stepwise forward with alpha < 0.05 to enter a predictor. Possible predictors include the type of the aneurysm (ruptured or unruptured), location, size of the aneurysm, size of the neck of the aneurysm as well as other baseline characteristics.
Recruitment rate and centers
The targeted lesions are the most frequent lesions treated in endovascular centers; thus we expect at least 10-20 patients per year per center. We need to recruit 20-25 centers that will recruit 10-20 patients/ year for two to three years in order to reach the necessary sample size. Centers will be experienced in endovascular treatment of aneurysms (at least 100 aneurysms will have been treated previously).
Duration of the trial
We plan a three-to four-year recruitment phase, followed by a follow-up period of 12 months for all patients. The trial should be completed within five to six years, including data analysis.
Protection against bias
Classic biases such as selection bias or information bias will be dealt with by randomizing patients and blinding in the assessment of the primary outcome. Random allocation of treatment is best for ensuring internal validity and is the best approach to control for confounding and selection bias. Finally, control variables will be measured and compared between treatment groups in order to ensure group comparability (initial angiographic success, periprocedural events, and disease characteristics).
Regulatory and ethical considerations
The Institutional Review Board of the Centre Hospitalier de l'Universite´de Montre´al approved the protocol on November 1, 2013 (Study ID: 13-092). Participants will be made fully aware of the study purposes, the procedure and the risks of each intervention. When signing the study consent form, they will be informed that participation is voluntary and they could request to be withdrawn from the study at any time. Patient enrollment in this trial will comply with the principles enunciated in the Declaration of Helsinki. All the information collected with the questionnaires will be kept confidential and will be used on an anonymous basis. DELTA is meant to be a clinical research project within the International Consortium of Neuro-Endovascular Centres (ICONE) framework. 16 Trial management is transparent, fully independent, and aims at preserving the scientific integrity of the research enterprise and the welfare of the participants. The industry has no control over the design or conduct of the trial, and no access to the data will be granted until publication; the results will be published whether they are favorable or not, and publications will be fully independent and autonomous. The SC has full responsibility regarding the conduct and progress of the trial, as well as reporting of results. The SC will not have access to the unmasked data before completion or interruption of the trial. The clinical events committee, the endpoint review committee, and the adverse event committee, once nominated, will work independently from the SC. These committees regularly send progress reports, notices and warnings when appropriate, to the independent DSMC. The committees that would have access to unmasked data are limited to the adverse event committee (responsible for reviewing each adverse event) and the DSMC (any time members judge that unmasking of groups is mandatory to protect the safety of participants, or once they are convinced that significantly different results have occurred). The DSMC will follow the progress of the trial, results and events being masked (tagged as group A and B) at all times, but with the possibility of unmasking results in case of necessity. The DSMC will inform the SC if the trial should be interrupted if any concern arises during the trial. The SC will act according to the DSMC recommendations.
Discussion
DELTA is a randomized clinical trial designed to determine whether the one-year efficacy of endovascular coil embolization can be improved by using a larger-caliber coil system. Other than using larger coils, the trial is designed to not alter routine coiling practices, and grants full technical freedom to the neuro-interventionist. The study is carried out using routine care personnel who collect data on simple web-based CRFs according to normal routine clinical practice. No additional tests or imaging is required by the trial other than what normally is practiced in each local center.
Packing density was conceived as an easily measured estimate of the extent to which an aneurysm is filled with embolic coiling material. [17] [18] [19] It is a continuous, quantitative variable representing the ratio of the volume of coils to the total volume of the aneurysmal sac that can be calculated with relative ease. Packing density is thought to play a role in estimating with ''objectivity'' the success of the initial endovascular treatment, at least as compared to other more subjective endpoints, such as angiographic results. 13 Although an increased risk of angiographic recurrences has been associated with inferior packing density in some observational studies, 9, [20] [21] [22] [23] [24] its value in predicting inferior follow-up angiographic results remains controversial 23, 25 and randomized evidence is not available. Residual and recurrent aneurysms on follow-up imaging studies have been shown to occur more frequently in patients with ruptured aneurysms, in large aneurysms, in wide-necked aneurysms, and in aneurysms that are incompletely occluded after the initial treatment. [8] [9] [10] [11] 14 Unfortunately, aneurysm volumes and neck sizes, incomplete initial occlusions and packing density, are not independent predictors of outcome. 9, 10, 22 Nevertheless, packing density often serves as a surrogate marker of the completeness of initial coiling. Packing density is not an end in itself, but it will still be used as an endpoint of the pilot phase because it is thought that if the use of largercaliber coils does not have an impact on packing density, it is unlikely then to change the treatment significantly enough to affect long-term angiographic results. Based on a previous observational study, 9 we hypothesize a modest increase in packing density (from 25% to 28%) allowing hence the inclusion of a sufficient number of patients during the pilot phase in order to verify other clinically significant secondary endpoints, such as safety, with limited power, however.
The method that will be used to calculate aneurysm volumes is not as accurate as more-exact experimental methods, 24, 26 but it is simple, immediately available, and in common clinical usage. Similar methods have been used in most published studies. 27 We expect an overestimation of all volumes (and an underestimation of packing density), but errors in the estimates should be similar for both randomized groups.
Finally, coiling is performed to prevent aneurysm ruptures, but the primary outcome cannot be limited to hemorrhagic events, estimated to be quite rare, in the range of 0.1%-1% per year. Thus angiographic results on follow-up imaging studies are the most frequently used surrogate marker of treatment efficacy in all previous major coil trials. 7, 8, 28, 29 Trial status DELTA is now recruiting interested centers for participation in the study. At the time of manuscript submission, 120 patients have been randomized and treated in 10 active centers in North America.
